Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Abstract:

:Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome the drug delivery problems of matrix-based sustained release forms by releasing the drug at a relatively constant rate over a 24-hour period, and thus producing sustained and consistent metoprolol plasma concentrations and beta 1-blockade while retaining the convenience of once daily administration. Clinically and statistically significant reductions in blood pressure have been observed with metoprolol CR/ZOK and metoprolol OROS 24 hours after administration in mildly or moderately hypertensive patients. Studies in patients with mild to moderate hypertension have demonstrated that a similar or higher percentage of patients achieved a goal response with metoprolol CR/ZOK compared with matrix-based sustained release formulations of metoprolol, or conventional atenolol or bisoprolol, while metoprolol OROS achieved an equal or greater response rate compared with conventional or matrix-based sustained release metoprolol preparations. In patients with stable effort angina pectoris, once daily administration of metoprolol CR/ZOK provided at least equal antianginal efficacy as conventional metoprolol in divided doses, while metoprolol OROS reduced the mean number of anginal attacks by the same margin as atenolol. Controlled release metoprolol formulations have been well tolerated in clinical trials. Metoprolol CR/ZOK was associated with a similar or lesser degree of adverse effects related to the central nervous system compared with atenolol or long acting propranolol. Metoprolol CR/ZOK also demonstrated less pronounced beta 2-mediated bronchoconstrictor effects than atenolol in asthmatics, and less general fatigue and leg fatigue in healthy subjects. Metoprolol OROS produced less pronounced bronchoconstrictor effects than atenolol, matrix-based sustained release metoprolol or long acting propranolol in patients with asthma or obstructive airways disease, and healthy volunteers. These results are presumably due to the beta 1-selectivity of metoprolol in addition to the relatively low plasma concentrations maintained by metoprolol CR/ZOK and metoprolol OROS, and the avoidance of high peak plasma concentrations with these agents. Despite the relative safety of the controlled release forms of metoprolol, the use of all beta-adrenoceptor antagonists should be avoided in patients with a history of bronchospasm. Thus, controlled release metoprolol formulations offer the potential to maximise the confirmed benefits of this agent in the management of hypertension and angina, by maintaining clinically effective plasma concentrations within a narrow therapeutic range over a 24-hour dose interval.

journal_name

Drugs

journal_title

Drugs

authors

Plosker GL,Clissold SP

doi

10.2165/00003495-199243030-00006

subject

Has Abstract

pub_date

1992-03-01 00:00:00

pages

382-414

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

43

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.

    abstract::Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800354-00012

    authors: Sandberg M,Foale RA

    更新日期:1988-01-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00

  • Parenteral aminoglycoside therapy. Selection, administration and monitoring.

    abstract::Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447060-00004

    authors: Kumana CR,Yuen KY

    更新日期:1994-06-01 00:00:00

  • Voriconazole : a review of its use in the management of invasive fungal infections.

    abstract::Voriconazole (VFEND), a synthetic second-generation, broad-spectrum triazole derivative of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth. In the US, intravenous and/or oral voriconazole is recommended in adul...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767020-00009

    authors: Scott LJ,Simpson D

    更新日期:2007-01-01 00:00:00

  • Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity.

    abstract::Childhood obesity has become the most common paediatric disorder in the developed world. Treatment of obesity in children may include lifestyle interventions, pharmacotherapy and weight-loss supplements. The outcome of lifestyle interventions, which classically include dietary modifications, increased activity and beh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11319210-000000000-00000

    authors: Rogovik AL,Chanoine JP,Goldman RD

    更新日期:2010-02-12 00:00:00

  • Tuberculosis vaccines: current progress.

    abstract::Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to comb...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200565170-00002

    authors: Orme IM

    更新日期:2005-01-01 00:00:00

  • Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0666-0

    authors: Garnock-Jones KP

    更新日期:2017-01-01 00:00:00

  • Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

    abstract::Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11597520-000000000-00000

    authors: Tetrault JM,Fiellin DA

    更新日期:2012-01-22 00:00:00

  • Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835020-00003

    authors: Langley MS,Heel RC

    更新日期:1988-02-01 00:00:00

  • Pharmacological interventions for the induction of ovulation.

    abstract::Ovulation induction is the most common medical intervention for the treatment of infertility. Clomifene is generally the first treatment choice for patients with amenorrhoea, unless there is profound hypothalamic deficiency. When clomifene fails to induce ovulation, menotropins (human menopausal gonadotrophin) or gona...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550030-00006

    authors: Collins JA,Hughes EG

    更新日期:1995-09-01 00:00:00

  • Tofacitinib: A Review in Rheumatoid Arthritis.

    abstract::Tofacitinib (Xeljanz®) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are int...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0835-9

    authors: Dhillon S

    更新日期:2017-12-01 00:00:00

  • Meloxicam.

    abstract::Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis. It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the const...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651030-00007

    authors: Noble S,Balfour JA

    更新日期:1996-03-01 00:00:00

  • Nivolumab: a review of its use in patients with malignant melanoma.

    abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0234-4

    authors: Deeks ED

    更新日期:2014-07-01 00:00:00

  • Abiraterone acetate: in metastatic castration-resistant prostate cancer.

    abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11208080-000000000-00000

    authors: Yang LP

    更新日期:2011-10-22 00:00:00

  • Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.

    abstract::Delamanid (Deltyba(®)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0331-4

    authors: Blair HA,Scott LJ

    更新日期:2015-01-01 00:00:00

  • Brexpiprazole: First Global Approval.

    abstract::Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0462-2

    authors: Greig SL

    更新日期:2015-09-01 00:00:00

  • Prevention of transplant rejection: current treatment guidelines and future developments.

    abstract::In the past 2 decades, progressive improvements in the results of organ transplantation as a therapeutic strategy for patients with end-stage organ disease have been achieved due to greater insight into the immunobiology of graft rejection and better measures for surgical and medical management. It is now known that T...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754040-00003

    authors: Perico N,Remuzzi G

    更新日期:1997-10-01 00:00:00

  • Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

    abstract::Endothelial dysfunction and increased arterial stiffness occur early in the pathogenesis of diabetic vasculopathy. They are both powerful independent predictors of cardiovascular risk. Advances in non-invasive methodologies have led to widespread clinical investigation of these abnormalities in diabetes mellitus, gene...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565010-00003

    authors: Woodman RJ,Chew GT,Watts GF

    更新日期:2005-01-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

    abstract::The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00012

    authors: Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

    更新日期:1985-01-01 00:00:00

  • Inflammatory processes in bronchial asthma.

    abstract::Bronchial asthma is an inflammatory disease. The characteristic pathological features of epithelial cell loss, goblet cell hyperplasia, increased deposition of collagen beneath the basement membrane, mast cell degranulation, and inflammatory cell infiltration of the mucosa are not limited to fatal asthma. Similar infl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198900371-00021

    authors: Beasley R,Roche W,Holgate ST

    更新日期:1989-01-01 00:00:00

  • Use of economic evaluation in decision making: evidence and recommendations for improvement.

    abstract::Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a num...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11538120-000000000-00000

    authors: Simoens S

    更新日期:2010-10-22 00:00:00

  • Pharmacology and therapeutic use of calcitonin.

    abstract::Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121040-00002

    authors: Stevenson JC,Evans IM

    更新日期:1981-04-01 00:00:00

  • Spread the Word: There Are Two Opioid Crises!

    abstract::Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01342-8

    authors: Marchetti Calônego MA,Sikandar S,Ferris FD,Moreira de Barros GA

    更新日期:2020-08-01 00:00:00

  • Fetal pharmacotherapy.

    abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262050-00004

    authors: Koren G,Klinger G,Ohlsson A

    更新日期:2002-01-01 00:00:00

  • Tranexamic acid: a review of its use in surgery and other indications.

    abstract:UNLABELLED:Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules. Intravenously administered tranexamic acid (most commonly 10 mg/kg followed by infusion of 1 mg/kg/hour) caused reductio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00017

    authors: Dunn CJ,Goa KL

    更新日期:1999-06-01 00:00:00

  • Lung tissue penetration of temocillin.

    abstract::Eight patients about to have the whole or part of a lung resected were given a 2g bolus dose of temocillin. A series of serum samples and a piece of peripheral lung tissue were collected and assayed for temocillin concentration. 30 minutes after drug administration, the mean serum and tissue concentrations were 172 mg...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00031

    authors: Cowan W,Baird A,Sleigh JD,Gray JM,Leiper JM,Lawson DH

    更新日期:1985-01-01 00:00:00

  • Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

    abstract::Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464160-00003

    authors: DiFrancesco D,Camm JA

    更新日期:2004-01-01 00:00:00

  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Digoxin use in congestive heart failure. Current status.

    abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855060-00002

    authors: Riaz K,Forker AD

    更新日期:1998-06-01 00:00:00